Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome

Elisa Unti¹ | Sonia Mazzucchi² | Rosanna Calabrese² | Giovanni Palermo³ | Eleonora Del Prete³ | Ubaldo Bonuccelli³ | Roberto Ceravolo³

¹Neurology Unit, Ospedale Apuano, Massa, Italy
²Neurology Unit, Department of Medical Specialties, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
³Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Correspondence
Roberto Ceravolo, Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Email: roberto.ceravolo@unipi.it

Abstract
Background: Dystonia is a key symptom in corticobasal syndrome (CBS), and upper limb dystonia is the most common phenotype. Dystonia-associated pain is frequently reported and can be disabling, with poor benefit from oral treatments.

Aims of the Study: To investigate the role of botulinum toxin A (BoTNA) in the treatment of dystonia and associated pain in CBS.

Methods: Ten consecutive patients with a clinical diagnosis of probable CBS and dystonia with/without associated pain were treated with BoTNA every 3 months. Treatment efficacy was assessed during the first follow-up visit, three months after the first injection, by means of caregiver impression (CI), evaluation of muscle tone with the Ashworth scale (AS), severity of pain measured with the visual analog scale (VAS).

Results: Nine subjects underwent at least three treatments, four patients discontinued for progressive reduction in efficacy or disease progression, five patients are ongoing with good response, and one completed the 10th treatment. No local or systemic side effects were reported, and levodopa equivalent daily dose remained unchanged in most cases during the observational period. Significant improvement of AS was recorded (from 2.9 ± 0.7 to 2.0 ± 0.5, p = 0.003). CI ranged from mild to moderate benefit. All patients reported efficacy on pain, with a significant reduction of VAS score (from 7.7 ± 1.7 to 1.7 ± 0.7 in the Pain group, p = 0.016).

Conclusions: Our study confirms safety, efficacy, and tolerability of BoTNA in the treatment of dystonia associated with CBS. Local treatment should be considered as a valid alternative to oral treatment modulation mainly in the presence of associated pain.

Keywords: botulinum toxin, corticobasal syndrome, dystonia, pain
Corticobasal degeneration (CBD) is a rare neurodegenerative disease included in the group of tauopathies. According to pathologically proven cases and current diagnostic criteria (Alexander et al., 2014; Armstrong et al., 2013; Stamelou, Alonso-Canovas, & Bhatia, 2012), the disease may present with different phenotypes, mainly as corticobasal syndrome (CBS), but also as progressive supranuclear palsy syndrome, frontotemporal dementia, and nonfluent primary progressive aphasia. The term CBS is currently preferred to CBD (Stamelou et al., 2012) when referring to cases without anatomopathological confirm. Probable CBS is defined by the asymmetric presentation of two motor symptoms (limb rigidity/akinesia, limb dystonia, limb myoclonus) associated with two nonmotor features (orobuccal/limb apraxia, cortical sensory deficit, alien limb phenomena). Mean disease duration is 6.6 years (range 2–12.5 years). Limb rigidity is present in the majority of cases during the overall course of the disease (85%), whereas dystonia affects a variable percentage of subjects (Armstrong et al., 2013). The onset of dystonic symptoms usually occurs during the first 2 years from diagnosis but can be delayed up to 4 years. The dystonic pattern is variable, and upper limb is the most commonly affected, whereas in minority of cases, cervical dystonia, blepharospasm, and lower limb dystonia can be observed (Stamelou et al., 2012). Upper limb dystonia can present as a posture typically defined “dystonic clenched fist,” characterized by flexion and adduction of arm, forearm, wrist, and metacarpophalangeal joints, with the extension of interphalangeal joints (Cordivari, Misra, Catania, & Lees, 2001). Associated pain is frequently reported and can be disabling.

Therapeutical strategies in CBS are limited and mainly rely on the treatment of motor symptoms. Parkinsonism can benefit from levodopa in a minority of cases whereas dystasia is usually not responsive, with dose increase often unsuccessful and poorly tolerated. Benefit on dystonic symptoms from nondopaminergic treatments such as benzodiazepines, anticholinergics, or baclofen is rare. Presence and severity of pain associated with dystonic posture were measured with the visual analog scale (VAS, 0–10) and recorded during all the observational period. After clinical and electrophysiological evaluation, patients were treated with BoTNA (T0). Selection of muscles depended on clinical phenotype and neurophysiological recordings (Table 1). All patients were injected with abobotulinumtoxinA (Dysport, dilution: 500 UI in 2.5 ml of saline). Treatment efficacy was evaluated during the follow-up visit performed 3 months after the first injection (T1) taking into account patient’s and caregiver’s impression (CI). CI was expressed by means of a specific scale ranging from 0 to 3 (0 = no efficacy, 1 = mild benefit, 2 = moderate benefit, and 3 = significant benefit). The CI and VAS scores were obtained at T1 but they were referred to the period of maximum efficacy of the treatment. The Ashworth score was measured at T1. An intermediate visit was not performed between T0 and T1 to reduce patients’ discomfort.

Data were analyzed with SPSS version 24, using nonparametric statistical tests. The significance level in all statistical tests was set to 0.05. Wilcoxon signed-rank test was used to compare median levodopa equivalent daily dose (LED, VAS, and AS) before and after treatment. Correlations were assessed using Spearman’s rank correlation coefficient.

Ten consecutive patients (females, mean age 74.8 ± 4.9 years) were included in the study (Table 1). Dystonia affected the upper limb
in nine patients, and one had cervical dystonia. In all cases, levodopa treatment at T0 was ongoing with unsatisfactory results (mean LEDD 593.5 ± 276.6, median 675.0). At T0, mean injected dose of abobotulinumtoxinA was 297.0 ± 145.8 UI, disease duration was 40.6 ± 25.5 months, and mean AS was 2.9 ± 0.7. Seven patients complained of pain associated with dystonia, with mean T0 VAS score of 5.4 ± 4.0 considering the whole population and 7.7 ± 1.7 in the group reporting pain (Pain group). Correlations between AS and VAS score were not observed at T0 ($p = 0.253$).

Patients were followed up and injected every 3 months up to 30 months. No local or systemic side effects were reported. One patient discontinued after the second treatment due to lack of

---

**TABLE 1 Clinical details before (T0) and after the first treatment (T1)**

| Patient | Age | Disease duration (months) at T0 | Type of dystonia | Injected muscles | BoTNA total dose (UI) | VAS score T0 | VAS score T1 | AS T0 | AS T1 | Functional effect | Caregiver impression |
|---------|-----|---------------------------------|------------------|-----------------|----------------------|--------------|--------------|--------|--------|------------------|----------------------|
| 1       | 73  | 72                              | Left arm         | Left biceps, triceps, brachioradialis, flexor digitorum profundus | 500           | 8            | 0            | 3      | 2      | No               | 2                    |
| 2       | 76  | 36                              | Neck             | Trapezius, splenium capitis, sternocleidomastoid               | 320           | 0            | 0            | 3      | 2      | No               | 2                    |
| 3       | 79  | 14                              | Left arm         | Left biceps, brachioradialis                                   | 300           | 8            | 0            | 3      | 2      | No               | 2                    |
| 4       | 82  | 36                              | Right arm        | Right biceps, triceps, brachioradialis, flexor digitorum profundus | 500           | 0            | 0            | 4      | 3      | No               | 0                    |
| 5       | 69  | 96                              | Right arm        | Right biceps, triceps, brachioradialis                         | 350           | 0            | 0            | 3      | 2      | No               | 0                    |
| 6       | 69  | 48                              | Left arm         | Left Biceps, brachioradialis                                   | 380           | 9            | 1            | 3      | 2      | No               | 1                    |
| 7       | 68  | 36                              | Left arm         | Left flexor digitorum superficialis, lumbricalis               | 80            | 8            | 0            | 1      | 1      | Yes              | 3                    |
| 8       | 80  | 24                              | Left arm         | Left biceps, triceps, brachioradialis, flexor digitorum profundus | 240           | 6            | 1            | 3      | 2      | No               | 2                    |
| 9       | 76  | 24                              | Right arm        | Right biceps, brachioradialis                                   | 100           | 5            | 0            | 3      | 2      | No               | 1                    |
| 10      | 76  | 20                              | Right arm        | Right biceps, brachioradialis                                   | 200           | 10           | 1            | 3      | 2      | No               | 1                    |

*Note. BoTNA: botulinum toxin A; VAS: visual analog scale.*
TABLE 2  Mean clinical scores before (T0) and after the first treatment (T1)

|                          | T0          | T1          | p     |
|--------------------------|-------------|-------------|-------|
| Visual analog scale (0–10)|             |             |       |
| Study population         | 5.4 ± 4.0   | 0.3 ± 0.5   | 0.016 |
| Pain group               | 7.7 ± 1.7   | 0.4 ± 0.5   |       |
| Ashworth score (0–4)     | 2.9 ± 0.74  | 2.0 ± 0.5   | 0.003 |
| Caregiver impression (0–3)|           |             |       |
| Study population         | 1.4 ± 0.9   |             |       |
| Pain group               | 1.7 ± 0.7   |             |       |

efficacy, and 9 subjects underwent at least three treatments. Four patients discontinued, respectively, after 3rd (n = 1), 4th (n = 1), and 6th (n = 2) injection for progressive reduction in benefit or disease progression. Five patients are ongoing with good response, and one subject completed the 10th treatment.

LEDD remained unchanged in most cases during the observational period (mean LEDD at last treatment 631.0 ± 178.0, median 625.0), without significant differences between first and last treatment ($Z = -0.736, p = 0.461$). Levodopa dose increase was limited by side effects in three cases (hypotension, behavioral problems) and progression of dysphagia in one case. All subjects reported poor benefit on motor symptoms from oral treatment.

At T1, mean AS was 2.0 ± 0.5, with a significant reduction of median values (median T0: 3.0 median T1: 2.0; $Z = -3.0, p = 0.003$; Table 2). CI ranged from mild to moderate benefit, with mean score 1.4 ± 0.9 in the whole population and 1.7 ± 0.7 in the Pain group. Improvement was observed on passive movements, hand hygiene, and quality of sleep. Functional improvement of the hand was reported only in the subject with AS = 1 at T0.

All patients complaining of pain at T0 reported a sustained benefit, with mean VAS score at T1 of 0.3 ± 0.5 in the whole population and 0.4 ± 0.5 in the Pain group. The VAS reduction was statistically significant (median T0: 7.0 median T1: 0; $Z = -2.414, p = 0.016$). In three cases, remission of pain was not complete at T1, but further benefit was observed after the following treatments. Effect on pain remained stable over time even in those patients who discontinued treatment due to progressive loss of motor benefit.

No correlation was found between duration of treatment, expressed as number of treatments, and VAS score ($p = 0.847$), AS ($p = .161$), or disease duration at T0 ($p = 0.849$). CI at T1 showed correlation with the number of treatments ($p = 0.005$).

5 | DISCUSSION

The main aim of our study was to investigate efficacy of BoTNA in the treatment of dystonia and associated pain in CBS patients.

Our data confirm safety of BoTNA in CBS and its better tolerability with respect to oral treatment.

As previously reported (Kompoliti et al., 1998), dopaminergic therapy is unsatisfactory both on parkinsonism and on dystonia in the majority of patients and it is frequently associated with side effects (30% cases in our population). Nevertheless, local treatment with BoTNA is rarely offered to CBS patients.

In our cohort, it was not possible to demonstrate functional improvement, possibly limited by mean disease duration at T0 (40.6 months); however, similar results were reported in previous studies as part of the natural history of the disease. According to our results, local treatment can be helpful in a multimodal way, first of all by reducing hypertonia ($p = 0.003$), facilitating hygiene and passive movements. Muscle tone reduction observed could have been underestimated due to low specificity of the Ashworth scale and lack of an intermediate evaluation between T0 and T1.

Cognitive impairment of treated patients could have affected perception of efficacy. CI scale was used to add an objective measure of treatment efficacy and to evaluate real impact on quality of life. Mild to moderate benefit reported by caregivers, more pronounced in the Pain group, supports reliability of patients’ impression.

Significant pain reduction was reported by all seven subjects ($p = 0.016$), with complete remission after the first injection in four patients. Pain is a disabling symptom affecting quality of life, and oral drugs are often burdened by side effects and cognitive worsening. Efficacy of BoTNA on dystonic pain in CBS has been reported, but validated outcome measures are not currently available. In a recent retrospective study, pain response was evaluated using the Clinical Global Impression scale (Bruno et al., 2016), whereas VAS was used to report pain severity in dystonia related to advanced PD (Bruno et al., 2018).

Cognitive impairment in our patients could have limited the understanding of the VAS, and the subjective relief on pain could be part of a placebo response; however, in the same subjects, previous oral treatments were ineffective and there was always agreement between patient and caregiver impression on pain improvement.

We observed that even if duration of global treatment efficacy was variable among subjects, in all cases benefit on pain remained stable during the observational period and after discontinuation of BoTNA injections. In our cohort, pain associated with dystonia was not reported by all subjects and did not show a direct correlation with muscle tone, fixed posture, or disease duration. We hypothesized that efficacy of BoTNA on this symptom could be the result of a combined peripheral and central action, restoring possible dysfunctions of pain networks.

Secondary aim of our study was to identify predictors of good and prolonged response to improve selection of injected patients. According to our data, it is not possible to recognize statistically significant predictors, even if a positive CI suggests a prolonged efficacy expressed as total number of treatments ($p = 0.005$).

Our study has several limits, mainly the limited sample size and lack of a control group. Moreover, selection of patients was made on the basis of a clinical diagnosis of probable CBS.
To our knowledge, this is the largest CBS population treated with BoTNA and evaluated with outcome measures focused on muscle tone and pain.

6 | CONCLUSION

The present study confirms the safety, efficacy, and tolerability of BoTNA in upper limb and cervical dystonia associated with CBS.

Our results underline the importance to consider local treatment as a valid alternative to oral treatment modulation, mainly in patients complaining of pain associated with dystonia.

CONFLICT OF INTEREST

All the authors report no conflict of interest.

ORCID

Roberto Ceravolo https://orcid.org/0000-0003-1412-9406

REFERENCES

Alexander, S. K., Rittman, T., Xuereb, J. H., Bak, T. H., Hodges, J. R., & Rowe, J. B. (2014). Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. *Journal of Neurology, Neurosurgery and Psychiatry, 85*(8), 925–929. https://doi.org/10.1136/jnnp-2013-307035

Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., & ... Weiner, W. J. (2013). Criteria for the diagnosis of corticobasal degeneration. *Neurology, 80*(5), 496–503. https://doi.org/10.1212/WNL.0b013e31827f0fd1

Bruno, V. A., Fox, S. H., Mancini, D., & Miyasaki, J. M. (2016). Botulinum toxin use in refractory pain and other symptoms in Parkinsonism.

Canadian Journal of Neurological Sciences, 43(5), 697–702. https://doi.org/10.1017/cjn.2016.279

Bruno, V., Freitas, M. E., Mancini, D., Lui, J. P., Miyasaki, J., & Fox, S. H. (2018). Botulinum toxin type A for pain in advanced Parkinson's disease. *Canadian Journal of Neurological Sciences, 45*(1), 23–29. https://doi.org/10.1017/cjn.2017.245

Cordivari, C., Misra, V. P., Catania, S., & Lees, A. J. (2001). Treatment of dystonic clenched fist with botulinum toxin. *Movement Disorders, 16*(5), 907–913. https://doi.org/10.10102/mds.1186

Kompoliti, K., Goetz, C. G., Boeve, B. F., Maraganore, D. M., Ahlskog, J. E., Marsden, C. D., & ... Riley, D. E. (1998). Clinical presentation and pharmacological therapy in corticobasal degeneration. *Archives of Neurology, 55*(7), 957–961. https://doi.org/10.1001/archneur.55.7.957

Marsili, L., Suppa, A., Berardelli, A., & Colosimo, C. (2016). Therapeutic interventions in Parkinsonism: Corticobasal degeneration. *Parkinsonism Related and Disorders, 22*(Suppl 1), S96–S100. https://doi.org/10.1016/j.parkreldis.2015.09.023

Müller, J., Wenning, G. K., Wissel, J., Seppi, K., & Poewe, W. (2002). Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. *Journal of Neurology, 249*(3), 300–304. https://doi.org/10.1007/s004150200009

Pacchetti, C., Albani, G., Martignoni, E., Godi, L., Alfonso, E., & Nappi, G. (1995). “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. *Movement Disorders, 10*(3), 333–336. https://doi.org/10.1002/mds.870100317

Stamelou, M., Alonso-Canovas, A., & Bhatia, K. P. (2012). Dystonia in corticobasal degeneration: A review of the literature on 404 pathologically proven cases. *Movement Disorders, 27*(6), 696–702. https://doi.org/10.1002/mds.24992

How to cite this article: Unti E, Mazzucchci S, Calabrese R, et al. Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome. *Brain Behav*. 2019;9:e01182. https://doi.org/10.1002/brb3.1182